RNASE4

Across TCGA pan-cancer cohorts, RNASE4 mass-spec protein differs between tumor and matched normal tissue in 7 of 18 cancer types tested, making tumor–normal expression one of RNASE4’s most consistent transcriptional readouts.

The strongest signal is observed in head and neck squamous cell carcinoma (HNSC), where RNASE4 mass-spec protein is repressed in tumor relative to normal tissue. In most cancer types RNASE4 is over-expressed in tumor, although a few such as HNSC and COAD show the opposite, repressed pattern.

HNSC, COAD, and LUAD are the cancer types where RNASE4 tumor–normal differential expression is most reproducible.

mass-spec protein tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in RNASE4 mass-spec protein (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
HNSC	All	All	−0.971	<.001	11	view →
COAD	Female	III,IV	−0.899	<.001	11	view →
LUAD	All	III,IV	−0.797	<.001	9	view →
LSCC	Female	All	−0.966	<.001	7	view →
CCRCC	Male	III,IV	−0.551	<.001	7	view →
PDAC	All	All	+0.477	<.001	6	view →
OV	All	All	−0.959	.011	2	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 7 strongest of 7 lineages.

RNASE4–HNSC

Open the HNSC breakdown →